NEONC TECHNOLOGIES HOLDINGS, INC. NTHI
Our company (f/k/a NAS-ONC, Inc.) was formed in 2008, devoted to developing new drugs with new delivery modes. As a clinical-stage biopharmaceutical company, we have focused on establishing treatments for intracranial malignancies, i.e., aggressive cancers located in the brain. These cancer types include primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers, that have arrived through metastatic spread from other cancers throughout the body, such as melanoma or breast and lung cancer. Brain- malignancies are particularly difficult to treat because the blood-brain barrier prevents efficient entry of most pharmacotherapeutic agents into the brain. As a result, these patients are faced with poor prognoses and shortened average life expectancy. NeOnc is developing novel drug delivery methods to be used in combination with novel drug candidates.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $40.0K | $83.0K | — |
| R&D | $3.6M | $3.0M | — |
| SG&A | $4.8M | $1.7M | — |
| Total operating expenses | $58.3M | $7.2M | — |
| Operating income | -$58.2M | -$7.1M | — |
| Interest expense | $2.5M | $2.6M | — |
| Net income | -$62.1M | -$11.9M | — |
| EPS, basic | -3.20 | -0.69 | — |
| EPS, diluted | -3.20 | -0.69 | — |
| Shares, diluted (wtd. avg.) | $19.4M | $17.3M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Cash and equivalents | $58.7K | $64.9K | $31.9K |
| Total current assets | $1.4M | $2.2M | — |
| Total assets | $2.8M | $3.4M | — |
| Accounts payable | $6.1M | $2.9M | — |
| Total current liabilities | $20.0M | $8.9M | — |
| Total liabilities | $20.3M | $8.9M | — |
| Retained earnings | -$112.8M | -$50.6M | — |
| Total equity | -$17.5M | -$5.5M | -$14.0M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Operating cash flow | -$20.4M | -$4.2M | — |
| Stock-based compensation | $35.6M | — | — |
| Capital expenditure | $500.0K | — | — |
| Investing cash flow | -$500.0K | — | — |
| Financing cash flow | $20.9M | $4.2M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001829126-26-004495.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |